Valuation: TScan Therapeutics, Inc.

Market Cap 68.62M 60.05M 55.34M 51.29M 97.37M 6.51B 98.94M 664M 258M 3.21B 258M 252M 11.11B P/E 2026 *
-1.2x
P/E 2027 * -1.14x
Enterprise Value -30.25M -26.47M -24.4M -22.61M -42.92M -2.87B -43.62M -293M -114M -1.42B -114M -111M -4.9B EV / Sales 2026 *
-4x
EV / Sales 2027 * -0.79x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-27 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day+2.38%
1 week+10.19%
Current month+10.19%
1 month+8.66%
3 months+0.93%
6 months-8.47%
Current year+8.00%
1 week 0.98
Extreme 0.98
1.12
1 month 0.83
Extreme 0.8251
1.12
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
05-20Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
+2.38%+10.19%-25.52%-53.04% 68.62M
-0.10%+0.10%+74.33%+133.26% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+0.38%+1.25%-14.39%-11.84% 23.75B
+1.08%+5.84%+16.40%+468.20% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+3.14%+5.16%+29.57%+196.32% 13.96B
Average +0.57%+5.74%+48.15%+128.15% 24.36B
Weighted average by Cap. -0.39%+3.34%+57.91%+139.28%

Financials

2026 *2027 *
Net sales 7.56M 6.61M 6.1M 5.65M 10.72M 717M 10.9M 73.08M 28.42M 354M 28.37M 27.76M 1.22B 7.81M 6.83M 6.3M 5.84M 11.08M 741M 11.26M 75.5M 29.36M 366M 29.31M 28.68M 1.26B
Net income -115M -101M -92.8M -86.02M -163M -10.92B -166M -1.11B -433M -5.39B -432M -423M -18.63B -125M -109M -101M -93.3M -177M -11.85B -180M -1.21B -469M -5.85B -469M -458M -20.21B
Net Debt -98.87M -86.52M -79.74M -73.91M -140M -9.38B -143M -956M -372M -4.63B -371M -363M -16.01B -74.76M -65.42M -60.29M -55.88M -106M -7.1B -108M -723M -281M -3.5B -281M -275M -12.1B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
07/07/26 $1.080 +2.86% 534,880
06/07/26 $1.050 -0.94% 418,939
02/07/26 $1.060 -0.93% 879,505
01/07/26 $1.070 +9.17% 1,680,656
30/06/26 $0.9801 +0.27% 1,045,179
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.050USD
Average target price
6.000USD
Spread / Average Target
+471.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock